BeOne Medicines Statistics

Total Valuation

BeOne Medicines has a market cap or net worth of HKD 252.86 billion. The enterprise value is 240.93 billion.

Market Cap	252.86B
Enterprise Value	240.93B

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.54B
Shares Outstanding	n/a
Shares Change (YoY)	+1.47%
Shares Change (QoQ)	+4.62%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	75.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	121.86
PS Ratio	7.78
PB Ratio	9.29
P/TBV Ratio	9.42
P/FCF Ratio	n/a
P/OCF Ratio	153.28
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-78.92
EV / Sales	7.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-171.59

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.28.

Current Ratio	1.96
Quick Ratio	1.64
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-5.52
Interest Coverage	-15.99

Financial Efficiency

Return on equity (ROE) is -11.44% and return on invested capital (ROIC) is -4.16%.

Return on Equity (ROE)	-11.44%
Return on Assets (ROA)	-3.22%
Return on Invested Capital (ROIC)	-4.16%
Return on Capital Employed (ROCE)	-7.69%
Revenue Per Employee	2.95M
Profits Per Employee	-277,517
Employee Count	11,000
Asset Turnover	0.73
Inventory Turnover	1.35

Taxes

In the past 12 months, BeOne Medicines has paid 962.34 million in taxes.

Income Tax	962.34M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +63.14% in the last 52 weeks. The beta is 0.30, so BeOne Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.30
52-Week Price Change	+63.14%
50-Day Moving Average	149.17
200-Day Moving Average	135.61
Relative Strength Index (RSI)	44.08
Average Volume (20 Days)	7,086,517

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.31

Income Statement

In the last 12 months, BeOne Medicines had revenue of HKD 32.49 billion and -3.05 billion in losses. Loss per share was -28.81.

Revenue	32.49B
Gross Profit	27.56B
Operating Income	-2.31B
Pretax Income	-2.09B
Net Income	-3.05B
EBITDA	-949.23M
EBIT	-2.31B
Loss Per Share	-28.81

Full Income Statement

Balance Sheet

The company has 19.58 billion in cash and 7.76 billion in debt, giving a net cash position of 11.82 billion.

Cash & Cash Equivalents	19.58B
Total Debt	7.76B
Net Cash	11.82B
Net Cash Per Share	n/a
Equity (Book Value)	27.23B
Book Value Per Share	252.23
Working Capital	14.88B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.65 billion and capital expenditures -3.05 billion, giving a free cash flow of -1.40 billion.

Operating Cash Flow	1.65B
Capital Expenditures	-3.05B
Free Cash Flow	-1.40B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 84.81%, with operating and profit margins of -7.10% and -9.40%.

Gross Margin	84.81%
Operating Margin	-7.10%
Pretax Margin	-6.43%
Profit Margin	-9.40%
EBITDA Margin	-2.92%
EBIT Margin	-7.10%
FCF Margin	n/a

Dividends & Yields

BeOne Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.47%
Shareholder Yield	n/a
Earnings Yield	-1.21%
FCF Yield	-0.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BeOne Medicines has an Altman Z-Score of 4.11 and a Piotroski F-Score of 5.

Altman Z-Score	4.11
Piotroski F-Score	5